Approvals/TGA/OBIZUR susoctocog alfa (bhk) 500U antihemophilic factor (recombinant), porcine sequence powder for injection vial with water for injection syringe

Approved

STANDARD

OBIZUR susoctocog alfa (bhk) 500U antihemophilic factor (recombinant), porcine sequence powder for injection vial with water for injection syringe

Takeda Pharmaceuticals Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 29, 2025
Approval ID: 3c495e231cf7e582
Company: Takeda Pharmaceuticals Australia Pty Ltd
Type: Standard

Approval Details

Approval Id: 3c495e231cf7e582
Product Name: OBIZUR susoctocog alfa (bhk) 500U antihemophilic factor (recombinant), porcine sequence powder for injection vial with water for injection syringe
Artg Id: 236475
Artg Name: OBIZUR susoctocog alfa (bhk) 500U antihemophilic factor (recombinant), porcine sequence powder for injection vial with water for injection syringe
Sponsor: Takeda Pharmaceuticals Australia Pty Ltd
Company Detail Path: /organization/takeda-pharmaceuticals-australia-pty-ltd
Artg Date: 2016-04-29
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/a77244c7764d9814138795ffe70b336f.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/eb17a52aa61fe645d42fc1b4985bc326.pdf

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 29, 2025

Approval ID

3c495e231cf7e582

Type

Standard

Back to TGA Approvals